



## Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 19, 2026

BURLINGAME, Calif.--(BUSINESS WIRE)--Feb. 19, 2026-- Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in a fireside chat at the Oppenheimer 36<sup>th</sup> Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at 10:00 a.m. E.T. The conference will be held virtually.

A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at <https://investor.inva.com/presentations-events>. An archived replay of the webcast will be available following the fireside chat date.

### About Innoviva

Innoviva is a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets. Innoviva's royalty portfolio includes respiratory assets partnered with Glaxo Group Limited ("GSK"). Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva's other innovative healthcare assets include infectious disease and critical care assets stemming from acquisitions of Entasis Therapeutics, including XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of *Acinetobacter baumannii-calcoaceticus* complex and NUZOLVENCE® (zoliflodacin), a first-in-class, single-dose, oral antibiotic FDA-approved for the treatment of uncomplicated urogenital gonorrhea, including strains resistant to current first-line therapies, and La Jolla Pharmaceutical Company, including GIAPREZA® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA® (eravacycline) for the treatment of complicated intra-abdominal infections in adults. Innoviva also markets ZEVTERA (ceftobiprole), an advanced-generation cephalosporin antibiotic, in the U.S. through an exclusive license from Basilea Pharmaceutica International Ltd, Allschwil. For more information about Innoviva, please visit [here](#).

ANORO®, RELVAR® and BREO® are trademarks of the GSK group of companies. ZEVTERA is a trademark of Basilea Pharmaceutica Ltd, Allschwil.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20260219756566/en/): <https://www.businesswire.com/news/home/20260219756566/en/>

### Investor Relations (Internal):

Eleanor Barisser

Director, Investor Relations & Corporate Communications

[Eleanor.barisser@inva.com](mailto:Eleanor.barisser@inva.com)

### Investors and Media:

Argot Partners

(212) 600-1902

[innoviva@argotpartners.com](mailto:innoviva@argotpartners.com)

Source: Innoviva, Inc.